[go: up one dir, main page]

TW200501952A - Pirfenidone gel formulations - Google Patents

Pirfenidone gel formulations

Info

Publication number
TW200501952A
TW200501952A TW093104281A TW93104281A TW200501952A TW 200501952 A TW200501952 A TW 200501952A TW 093104281 A TW093104281 A TW 093104281A TW 93104281 A TW93104281 A TW 93104281A TW 200501952 A TW200501952 A TW 200501952A
Authority
TW
Taiwan
Prior art keywords
gel formulations
pirfenidone
formulations
pheny1
methy1
Prior art date
Application number
TW093104281A
Other languages
Chinese (zh)
Inventor
Ikeda Kaori
Yuichi Takasu
Kazumasa Morimoto
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of TW200501952A publication Critical patent/TW200501952A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

New gel formulations for treating fibrotic diseases are provided. The invention relates to gel formulations which comprise 5-methy1-1-pheny1-2-(1H)-pyridone, or a pharmaceutically acceptable salt or ester thereof.
TW093104281A 2003-02-21 2004-02-20 Pirfenidone gel formulations TW200501952A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003045110 2003-02-21

Publications (1)

Publication Number Publication Date
TW200501952A true TW200501952A (en) 2005-01-16

Family

ID=32905481

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093104281A TW200501952A (en) 2003-02-21 2004-02-20 Pirfenidone gel formulations

Country Status (2)

Country Link
TW (1) TW200501952A (en)
WO (1) WO2004073713A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5248040B2 (en) * 2007-05-25 2013-07-31 リードケミカル株式会社 Patch containing 5-methyl-1-phenyl-2- (1H) -pyridone
MX2007009796A (en) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel containing pirfenidone.
JP2010120912A (en) * 2008-11-21 2010-06-03 Lead Chemical Co Ltd Adhesive skin patch containing 5-methyl-1-phenyl-2-(1h)-pyridone
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
MX2011007675A (en) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans.
MX346763B (en) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V SEMISOLID TOPIC COMPOSITION CONTAINING PYRFENIDONE AND DIALYL MODIFIED DISULFIDE OXIDE (ODD-M) TO ELIMINATE OR PREVENT ACNE.
MX356551B (en) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne.
MX366086B (en) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage.
WO2022130410A1 (en) * 2020-12-16 2022-06-23 Cipla Limited Topical composition of pirfenidone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215719A (en) * 1989-02-15 1990-08-28 Yamauchi Akitomo Agent for repairing fibrosing lesion tissue and preventing fibrosing lesion
JP2610052B2 (en) * 1989-11-07 1997-05-14 信越化学工業株式会社 External gel base
CA2161648A1 (en) * 1993-05-07 1994-11-24 Solomon B. Margolin Compositions and methods for reparation and prevention of fibrotic lesions
WO2000016775A1 (en) * 1998-09-18 2000-03-30 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone

Also Published As

Publication number Publication date
WO2004073713A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
EP1790638A4 (en) Carbamoylpyridone derivative having hiv integrase inhibitory activity
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
MXPA05009508A (en) 6-substituted nicotinamide derivatives as opioid receptor antagonists.
WO2005065645A3 (en) Donepezil formulations
WO2005046603A3 (en) Pyridine compounds
AU2002950217A0 (en) 8- Hydroxy Quinoline Derivatives
SI1478358T1 (en) Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
LTC1830843I2 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
LU92761I2 (en) N-(5-hydroxy-2,4-diert-butyl-phenyl)-4oxo-1h-quinoline-3-carboxamide or a pharmaceutically acceptable salt thereof
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
IL179630A0 (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
MY145795A (en) Pyrazoline compounds
AP2005003451A0 (en) HIV integrase inhibitors.
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
TW200501952A (en) Pirfenidone gel formulations
DK1814848T3 (en) 2,3,4-substituted-cyclopentanones as therapeutic agents
WO2006001866A3 (en) Crystalline forms of n-desmethylclozapine
AU2003244181A1 (en) Phenoxypyridine derivative or salt thereof
WO2005007642A3 (en) Novel azaheterocyclic amides useful for treating pain
ZA200407358B (en) Microorganism for genetic therapeutic treatment ofproliferative diseases.
DE602005015323D1 (en) prostaglandin
AU2003267751A1 (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
AU2003269985A1 (en) Methods for increasing the rate of heart muscle contraction
MX2007002532A (en) Methods of treating proliferative skin diseases using carbazole derivatives.
GB0302315D0 (en) Novel therapeutic target